» Articles » PMID: 21040417

Maximum Conservative Management for Patients with Chronic Kidney Disease Stage 5

Overview
Journal Hemodial Int
Date 2010 Nov 3
PMID 21040417
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Following the expansion of dialysis services for patients with chronic kidney disease, an increasing number of elderly patients with varying degrees of frailty and additional comorbidities have been offered treatment. Life expectancy is somewhat limited in this group of patients, and initiation of dialysis may not necessarily improve quality of life. As such, an increasing number of centers are offering conservative care for patients who have made an informed decision not to have dialysis. As conservative care includes active treatment of anemia, volume overload, blood pressure control, and management of uremic symptoms, including pruritus, we term this approach as maximal conservative management of chronic kidney disease. We describe our experience of maximum conservative management, which although may not prolong life, can maintain the quality of life and functional ability until the final illness in the majority of patients. Although these patients do not go to the hospital on a regular basis, coordinated support from the hospital, the community, and the care giver/relative is required for successful care of the patient. Appropriate end of life planning can then be made according to the wishes of the patient.

Citing Articles

Disparities in treatment and outcome of kidney replacement therapy in children with comorbidities: an ESPN/ERA Registry study.

Schild R, Dupont S, Harambat J, Vidal E, Balat A, Bereczki C Clin Kidney J. 2023; 16(4):745-755.

PMID: 37007701 PMC: 10061422. DOI: 10.1093/ckj/sfad008.


Palliative Care for Patients with Kidney Disease.

Lanini I, Samoni S, Husain-Syed F, Fabbri S, Canzani F, Messeri A J Clin Med. 2022; 11(13).

PMID: 35807208 PMC: 9267754. DOI: 10.3390/jcm11133923.


Correlation between intestinal flora disruption and protein-energy wasting in patients with end-stage renal disease.

Hu J, Zhong X, Liu Y, Yan J, Zhou D, Qin D BMC Nephrol. 2022; 23(1):130.

PMID: 35369865 PMC: 8978364. DOI: 10.1186/s12882-022-02762-2.


Discussions during shared decision-making in older adults with advanced renal disease: a scoping review.

Raj R, Thiruvengadam S, Ahuja K, Frandsen M, Jose M BMJ Open. 2019; 9(11):e031427.

PMID: 31767590 PMC: 6887047. DOI: 10.1136/bmjopen-2019-031427.


Development of a mortality score to assess risk of adverse drug reactions among hospitalized patients with moderate to severe chronic kidney disease.

Danial M, Hassali M, Meng O, Kin Y, Khan A BMC Pharmacol Toxicol. 2019; 20(1):41.

PMID: 31287030 PMC: 6615098. DOI: 10.1186/s40360-019-0318-6.